Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinska AkadfiledCriticalMedizinska Akad
Priority to BG9052689ApriorityCriticalpatent/BG49665A1/en
Publication of BG49665A1publicationCriticalpatent/BG49665A1/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Abstract
The emitted by the line monoclonal antibody is applied for diagnostic purposes. The hybridoma line is highly productive, while the antibody - very specific. The registered in the NBICC under No. 1581 hybridoma cellular line is created through hybridization of mice myelomic cells of the line X63-Ag8.653 with splenocytes from an immunized with BALB/c mouse.
BG9052689A1989-12-011989-12-01Hybridom cell line, secreting monoclonal antibody against determinant 05 salmonelli of group b
BG49665A1
(en)
Monoclonal antibody to human helper t cells, method of preparing it, hybrid cell line producing it, its diagnostic and therapeutic uses and diagnostic and therapeutic compositions comprising it
Monoclonal antibody to human t cells, method for preparing it, hybrid cell line producing it, therapeutic composition comprising it and diagnostic method using it
Monoclonal antibody specific to a fibronectin sequence expressed in transformed cells, hybridoma secreting said antibody and use of said monoclonal antibody in the diagnosis of tumors
A monoclonal antibody against a human MDRI multidrug resistance gene product, and a method of using the same (A MONOCLONAL ANTIBODY TO A HUMAN MDRI MULTIDRUG RESISTANCE GENE PRODUCT, AND USES)
MONOCLONAL ANTIBODIES AND PRODUCTION OF A VACCINE AGAINST HUMAN CANCER ANTIGENS BY IMMUNIZATION WITH HUMAN AND ANIMAL MUCIN AND WITH SYNTHETIC GLUCIDEN CARRIER CONJUGATES.